Martek “clearly exceeded expectations” in the third quarter for new owner DSM within a nutrition division that continued to deliver “robust” results despite the negative impact of currency translation.
Seven months after sealing a billion dollar deal to acquire Martek, DSM has created Nutritional Lipids, a new division that will combine Martek’s algal omega-3 and omega-6 products and DSM Nutritional Products’ polyunsaturated fatty acid (PUFA) portfolio.
Algae Biosciences Corporation – a high-profile new entrant to the omega-3 fatty acid market – has unveiled detailed figures on anticipated production volumes after finalizing a deal to build the first phase of its new production facility near Holbrook...
Royal DSM’s acquisition of Martek Biosciences Corporation has moved a step closer to finalisation with the news that its tender offer to buy all of the company’s outstanding shares of common stock at a price of $31.50 (about €24) per share has proved...
Royal DSM will drive Martek’s predominantly US-based, omega-3 DHA infant nutrition business to new shores, and fast-track its food and beverage ambitions, after having its billion-dollar bid accepted by the Maryland company’s Board.
Increased sales of nutritional ingredients in both the infant formula and non-infant formula markets plus the acquisition of health and wellness company Amerifit helped Martek Biosciences achieve a 30 per cent increase in 2010 revenues to reach $450m.
Global omega-3 DHA leader Martek Biosciences Corporation has made a bold move into product manufacture with the $200m acquisition of Amerifit Brands, a company that specializes in women’s and digestive health products.
Martek Biosciences Corporation has announced plans to restructure
its plant operations, including the layoff of 15 percent of its
workforce, following a review of the company's current production
and cost structure.
Martek Biosciences has entered into a 15-year supply agreement,
that includes co-branding priviledges, with WhiteWave Foods for the
development of soy beverages containing Martek's flagship omega-3
With its new supply agreement with Mead Johnson Nutritionals,
Martek Biosciences solidifies its position in the world market for
DHA and ARA, as alternative omega-3 sources are approved for infant
A Maryland court has ruled in favor of Martek Biosciences in a
motion of summary judgment of an outstanding dispute with the
former interest holders of OmegaTech, the DHA producer it acquired
in March 2002.
Martek Biosciences has released its third quarter financial
results, with a steep 17 percent drop in sales. But although
operating income also took a dive, the poor quarter is not a sign
of waning interest in nutritional oils. Rather,...
The stockpiles of Martek products being held by the firm's
customers caused a slowdown in revenue growth for the second
quarter but it claims that extra capacity coming on stream this
year will see a new surge in demand, reports...
Shareholders who have become aware of an omega-6 mountain in the
stockrooms of Martek customers have filed a lawsuit seeking class
action status against the company, alleging that it flooded
customers with inventory in order to meet...
After a successful third quarter, Martek Biosciences will be hoping
that the Food and Drug Administration's (FDA) announcement last
week that conventional foods will now be able to display a
qualified health claim for omega-3...
Fatty acids producer Martek Biosciences continued its recent
profit-making run during the second quarter, which should help its
plans to expand further into new markets and new applications,
writes Philippa Nuttall.
DSM Food Specialties is to double the volume of arachidonic acid
(ARA) produced for its US partner Martek Biosciences to meet
rapidly growing demand, the Dutch firm said this week, writes
License agreements with leading infant formula makers helped Martek
Biosciences maintain a strong revenue stream in this year's first
quarter but although it has continued last year's profit-making run
through to 2004, margins...
Martek Biosciences said yesterday that the Food and Drug
Administration (FDA) has completed a favorable review of its safety
data on the former Omega Tech DHA product, currently being marketed
by the company for use in food applications.
Nutritional oil manufacturer Martek Biosciences recorded its first
annual profit this year since founding almost 20 years ago,
revealing a net income of $16 million compared to losses worth $24
million last year.
Martek Biosciences is to pay around $10 million for the assets of
contract fermentation business FermPro Manufacturing. The FermPro
facility will be used to produce extra quantities of its
microalgae-derived DHA and ARA fatty acids.
Martek Biosciences says it has signed a worldwide license agreement
with Nestec, the Nestle affiliate, for Martek's technology relating
to docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant
Martek Biosciences has reported a 132 per cent increase in revenues
to $26.4 million for the second quarter of the year, thanks to
greater sales of nutritional products to the company's infant
formula licensees, Wyeth, Mead Johnson...
Martek Biosciences, the US group which specialises in omega-3 oils,
has reported net losses of $3.7 million (€3.8m) for the third
quarter of the current year, but said that its restructuring
efforts were beginning to bear fruit.
Martek Biosciences Corporation is to buy docosahexaenoic acid (DHA)
producer OmegaTech, giving it a further foothold in the growing
market for fortified foods. Martek said it would become the world
leader in fermentation-derived DHA...
US company Martek Biosciences Corporation that develops,
manufactures and sells products from microalgae for nutritional
foods, announced recently that it has sold the assets of its stable
isotope business unit to Spectra Gases, Inc.,...